5.50MMarket Cap-423P/E (TTM)
1.6800High1.6100Low95.49KVolume1.6700Open1.6700Pre Close156.63KTurnover2.93%Turnover RatioLossP/E (Static)3.31MShares16.194052wk High1.18P/B5.41MFloat Cap0.920552wk Low--Dividend TTM3.26MShs Float183.0000Historical High--Div YieldTTM4.19%Amplitude0.9205Historical Low1.6400Avg Price1Lot Size
Clearmind Medicine Stock Forum
Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel psychedelic-derived therapeutics, has announced a engagement with JS First Sdn. Bhd (“JS First”). This partnership focuses on ...
https://www.fda.gov/news-events/press-announcements/fda-issues-first-draft-guidance-clinical-trials-psychedelic-drugs
SciSparc Ltd. (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies for disorders and rare diseases of the central nervous system, has recently announced that it has submitted an additional patent application to the United States Patent and Trademark Office (USPTO). This submission is...
Clearmind Medicine Obtains Ind Approval From the FDA to Start the Phase I/Iia Clinical Trial With Its Innovative Treatment for Alcoholism
Clearmind Medicine Announces Submission of US Patent Application for Treating Metabolic Syndrome and Weight-Loss
Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotechnology firm dedicated to the discovery and development of novel psychedelic-derived therapeutics, has announced its participation in the forthcoming Psychedelic Medicine – Israel 2024 conference. This event will be he...
No comment yet